NasdaqGS:RXRXBiotechs
Recursion Pharmaceuticals (RXRX) Sees Sales And Revenue Growth In Q2 2025
Recursion Pharmaceuticals (RXRX) reported significant growth in sales and revenue for Q2 and the first half of 2025 but also experienced widening net losses. The release of their Boltz-2 model underscored a commitment to innovation, which resonates positively in a market focusing on technological advancements. Meanwhile, broader markets, including the S&P 500, faced a 1.5% decline, affected by investor caution ahead of Federal Reserve Chair Powell's speech. Within this market context, the...